Introduction
Enalapril (MK421) is a recent addition to the family of orally active angiotensin converting enzyme (ACE) inhibitors which are proving of clinical use in the treatment of hypertension, congestive cardiac failure and ascites (Di Carlo et al., 1983; Heel et al., 1980; Johnston et al., 1982; Romankiewicz et al., 1983) .
Enalapril is a prodrug whose pharmacological activity is dependent on deesterification to enalaprilic acid (MK422) (Biollaz etal., 1982; Jackson et al., 1982; Johnston et al., 1983) . The aim of the study was to examine the in vitro conversion of enalapril to enalaprilic acid by human tissue and to examine the influence of hepatic dysfunction on this metabolism. This may have clinical significance in the use of this drug in disease states where liver dysfunction is part of the clinical syndrome.
Methods

Enalaprilic acid radioimmunoassay
Enalaprilic acid was assayed using a specific radioimmunoassay (Hitchens et al., 1981 min at 2,000 rev/min, 8 pRI aliquots of each sample were then taken and blown down to dryness. The residue was reconstituted with 8 pul of assay buffer and enalaprilic acid estimated by radioimmunoassay. Recovery from tissue homogenate of standard concentrations of enalaprilic acid of 100 ng/ml, 50 ng/ml, 25 ng/ml and 12.5 ng/ml were 91.6 ± 1.5 ng/ml, 51.9 ± 2.3 ng/ml, 24.2 ± 0.5 ng/ml and 12 + 0.7 ng/ml respectively, and was thus taken as 100% over the assay range. Results were converted to moles and standardised for unit protein concentration and unit time.
Experiments were carried out on post mortem tissue. A 1 g sample was cut and then homogenised in normal saline using a Polytron homogeniser (45 s at 15,000 rev/min) to produce a concentration of 200 mg wet weight/i ml.
The protein content of each homogenate was determined (Lowry et al., 1951) 
Results
Liver was the only tissue that produced appreciable conversion of enalapril to enalaprilic acid, with moderate activity detected in lung and minor activity in heart and splenic tissue (Figure 1 
